Cancer Stem Cells and Targeting Strategies

Luisa Barbato 1, Marco Bocchetti 1,2, Anna Di Biase 1 and Tarik Regad 1,*

1 The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham NG11 8NS, UK
2 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
* Correspondence: tarik.regad@ntu.ac.uk; Tel.: +44-(0)115-848-3501

Received: 5 July 2019; Accepted: 15 August 2019; Published: 18 August 2019

Abstract: Chemoresistance is a major problem in cancer therapy as cancer cells develop mechanisms that counteract the effect of chemotherapeutic compounds, leading to relapse and the development of more aggressive cancers that contribute to poor prognosis and survival rates of treated patients. Cancer stem cells (CSCs) play a key role in this event. Apart from their slow proliferative property, CSCs have developed a range of cellular processes that involve drug efflux, drug enzymatic inactivation and other mechanisms. In addition, the microenvironment where CSCs evolve (CSC niche), effectively contributes to their role in cancer initiation, progression and chemoresistance. In the CSC niche, immune cells, mesenchymal stem cells (MSCs), endothelial cells and cancer associated fibroblasts (CAFs) contribute to the maintenance of CSC malignancy via the secretion of factors that promote cancer progression and resistance to chemotherapy. Due to these factors that hinder successful cancer therapies, CSCs are a subject of intense research that aims at better understanding of CSC behaviour and at developing efficient targeting therapies. In this review, we provide an overview of cancer stem cells, their role in cancer initiation, progression and chemoresistance, and discuss the progress that has been made in the development of CSC targeted therapies.

Keywords: cancer stem cells (CSCs); chemoresistance; chemotherapy; therapy; microenvironment; cancer

1. Introduction

In 2018, the World Health Organization (WHO) asserted that cancer is responsible for the death of 9.6 million people worldwide [1]. The data also suggest that despite the availability of different drugs, their efficacy requires further improvement with a focus on cancer complexity. In this intricate system, cancer stem cells play a crucial role, as they mediate chemoresistance and cancer recurrence. It is now clear that cancer stem cells (CSCs) represent a small population of cancer cells within a tumour and that they have typical characteristics related to stem cells. Like their stem cell counterparts, CSCs possess ‘stemness’ properties which are reflected in their capacity to self-renew and to generate differentiated cells that contribute to tumour heterogeneity. CSCs appear to be generated from mutations affecting adult stem cells that are at the source of organogenesis and tissue homeostasis [2–4]. Although debates about their origin persist, there is an urgent and continuous need to better understand the function of CSCs in cancer initiation and progression and, more importantly, develop CSC-specific targeting strategies.

Chemotherapy induces apoptosis by damaging DNA and/or inhibiting mitotic division. However, this therapeutic option is valid for highly dividing cancer cells and therefore has the potential to “miss out” slow dividing cells, leading to cancer relapse and recurrence in treated patients. Unfortunately, follow up chemotherapy that attempted to destroy refractory cancers cells has been mostly unsuccessful and was associated with a decrease in survival rates of treated cancer patients [5,6]. Due to their slow rate of division, CSCs mediate chemoresistance and recurrence following chemotherapy; however,
additional mechanisms that confer CSCs a survival advantage include the expression of the ATP-binding cassette (ABC) transporters, a higher expression of aldehyde dehydrogenases (ALDHs), an increased resistance to apoptosis, and a timely activation of the DNA damage sensor and repair machinery [7]. Other mechanisms, that are not discussed in this review, involve epigenetic factors that play a role in regulating gene expression at the transcriptional or post-transcriptional levels [8,9]. All these properties and their clinical implications point to the importance of investigating and targeting CSCs.

It is well known that the microenvironment or niche is essential for stemness maintenance, and this also applies to CSCs where cell-cell interactions within the niche are required for CSCs’ role in cancer initiation and progression [10]. The CSC niche is a complex environment that contains different types of cells, such as cancer-associated fibroblasts (CAFs), endothelial and immune cells, and mesenchymal stem cells (MSCs). These cells communicate through secreted growth factors and cytokines to promote tumorigenesis, angiogenesis, invasion and metastasis. The microenvironment of CSCs also contributes to CSCs’ resistance to drugs and other cancer therapies, which promotes cancer recurrence [11]. Several therapeutic strategies have been developed to target CSCs with the aim of preventing cancer recurrence. Although progress has been made through the development of targeting strategies, their therapeutic efficacy remains insufficient due to the absence of specific targetable biomarkers. In this review, we provide an overview of CSCs, their role in cancer initiation and progression, and discuss the targeting strategies that are being developed to target these highly aggressive cancer cells.

2. Cancer Stem Cells

“Omnis cellula e cellula” (“every cell stem from another cell”), with those words Rudolf Virchow, a German pathologist, gave the base of the cellular pathology. He had already postulated that the disease is due to changes happening in normal cells and that a tumour originates from immature cells [12,13]. However, the term cancer stem cell was coined by Sajiro Makino through the identification of a subpopulation of cells that were resistant to chemotherapy and with genetic characteristics that were different from the Bulk [13]. It was through studies carried out using the in vitro colony formation assay that Makino theory could be confirmed, and that suggested that a tumour could have originated from cells that had characteristics attributable to stem cells [14]. Further confirmation of Virchow’s idea came later from experiments using acute myeloid leukaemia (AML) cells that led to the identification of a population of cells with a stem-like phenotype [15]. The authors identified a population of CD34⁺CD38⁻ AML stem cells that were capable of initiating AML in severe combined immune-deficient (SCID) mice. Although using a different set of markers, populations of CSCs were also found in other types of cancerous tissues, which confirmed their existence within other types of tumours and the role that they play in cancer initiation and progression [16–35]. Two main hypotheses have been proposed to explain how CSCs are originated within a tissue: the stochastic and the hierarchical models [36,37]. The stochastic model supports the hypothesis that any cell subjected to a specific set of somatic mutations could lead to the acquisition of self-renewal and differentiation properties that could contribute to tumour heterogeneity. On the other hand, the hierarchical model proposes that somatic mutations target specifically stem and progenitor cells that are hierarchically organized, resulting in the generation of self-renewing cancer stem and progenitor cells that produce differentiated progenies and recreate heterogeneous tumours [38]. In summary, CSCs are populations of cancer cells that have the stem cell properties of self-renewal and ability to generate differentiated progenies.

3. Cancer Stemness, Therapy Resistance and Cancer Recurrence

A major challenge in cancer therapy is associated with chemo-resistance and recurrence following chemotherapy [2,39]. In most cases, this resistance is associated with the presence, within tumours, of aggressive cancer cell populations that developed mechanisms of chemo-resistance responsible for unsuccessful therapies and leading to decreased survival rates of treated cancer patients
Several cancer studies identified these aggressive cancer populations as cancer stem cells (CSCs) (Table 1) [15,16,40–46]. CSC-mediated chemoresistance relies on several cellular mechanisms that include lower proliferation rates and the ability to intracellularly and enzymatically inactivate chemotherapeutic compounds (Figure 1B) [7].

**Figure 1.** Schematic representation of cancer stem cells (CSCs) and their role in chemoresistance. (A) Chemotherapy destroys most of the highly proliferative cancer cells. CSCs are less affected by chemotherapy and can re-initiate cancer and promote cancer progression. (B) CSCs possess several mechanisms that counteract the effect of chemotherapeutic compounds such as the ATP family of transporters, higher expression of the pro-survival factor BCL2 (B-cell lymphoma 2), higher expression of the detoxifying enzymes aldehyde dehydrogenases (ALDHs), a more efficient DNA damage response and a slower rate of cell division or dormancy.

**Table 1.** Cell surface markers (solid tumours) that are used for the identification and isolation of CSCs.

| Tumour          | Biomarkers             | References |
|-----------------|------------------------|------------|
| Breast cancer   | CD44+/CD24−low/ALDH+   | [16]       |
| Prostate cancer | CD44+/a2b1+/ALDH+      | [34]       |
| Melanoma        | ABCB5+                 | [17]       |
|                 | CD20+                  | [18]       |
|                 | CD271+                 |            |
| Glioblastoma    | CD133+                 | [20]       |
| Colon cancer    | CD133+/CD44+/ALDH+     | [21]       |
|                 | EpCAM+/CD44+/CD166+    | [22]       |
|                 | CD44+/CD24+            | [23]       |
|                 | CD33+/CD24+            | [24]       |
| Lung cancer     | CD133+                 |            |
|                 | CD44+                  |            |
|                 | ALDH+                  |            |
|                 | CD117+                 | [35,47]    |
| Gastric cancer  | CD133+                 |            |
|                 | CD44+/CD24+            | [25]       |
|                 | CD90+                  | [26]       |
|                 | CD44+/CD54+            |            |
| Head and neck cancer | CD44+/ALDH+     |            |
|                 | CD44+/CD66+            | [27]       |
| Ovarian cancer  | CD133+                 |            |
|                 | CD44+                  |            |
|                 | ALDH+                  |            |
|                 | CD117+                 | [28]       |
| Pancreatic cancer | CD133+/CD44+/CD24+/ESA+ | [29]   |
| Liver cancer    | CD133+                 |            |
|                 | CD44+                  |            |
|                 | CD90+                  | [30]       |
|                 | EpCAM+                 | [31]       |
|                 | CD13+                  | [32]       |
3.1. Low Proliferation Rate

Chemotherapy targets highly proliferative cells through DNA damage and inhibition of mitotic division; however, its action is limited when it applies to slow and non-dividing cancer cells such as CSCs [48–51]. Indeed, several studies have shown that CSCs, from different tissue origin, could resist the effect of a wide range of drugs such as doxorubicin, temozolomide, cisplatin, paclitaxel, etoposide and methotrexate [52]. Hence, following chemotherapy, which destroys the bulk of the tumour, CSCs remain on-site and can re-initiate tumorigenic and metastatic processes. Hence, developing therapies that target dormant or slow dividing cells is essential to prevent recurrent cancers.

3.2. Expression of ATP-Binding Cassette (ABC) Transporters

This large superfamily of membrane proteins functions in the transmembrane transport of various substrates by converting energy obtained from ATP hydrolysis [53]. Although the type of ABC transporters varies from one type of cancer to another, CSCs express high levels of these transporters, which contributes to an increased transport of chemotherapeutic compounds out of the cells, contributing therefore to CSC chemoresistance. Some ABC transporters are involved in the transport of a large number of drugs, while others transport only a few. For instance, the ABCC1 (ATP-binding cassette transporter C1) transporter also known as MRP1 (Multi Drug Resistance Protein 1), expressed by CSCs in glioblastoma, is involved in the efflux of a variety of therapeutic compounds including methotrexate, edatrexate, ZD1694, doxorubicin, daunorubicin, epirubicin, idarubicin, etoposide, vincristine, vinblastine, paclitaxel, irinotecan, SN-38, flutamide and hydroxyflutamide [54–56]. ABCB1 (ATP-binding cassette transporter B1), also known as MDR1 (Multidrug Resistance Protein 1), expressed by CSCs found in ovaries and breast cancers, acute myeloid leukaemia (AML), glioblastoma and renal cell carcinoma, provides drug multi-resistance to anthracyclines actinomycin D, colchicine, etoposide, teniposide, methotrexate, mitomycin C, mitoxantrone, paclitaxel, docetaxel, vincristine and vinblastine [57–60]. Other ABC transporters have a limited drug transport capacity, such as ABCA1 (ATP-binding cassette transporter A1), which is expressed by serous ovarian CSCs and which transports cisplatin [59]. In summary, ABCs are drug specific transporters that may require combination therapies that use inhibitors for the different transporters.

3.3. Increased Expression of Aldehyde Dehydrogenases (ALDHs)

This superfamily of enzymes is crucial for the detoxification of endogenous and exogenous aldehyde substrates by catalysing the oxidation of aldehydes to carboxylic acids [61–63]. They are highly expressed in CSCs from different types of cancers and their elevated levels of expression correlate with worse prognosis in cancer patients [64–66]. Although the mechanisms by which they promote CSC chemoresistance is not well known, this activity may involve their role in retinoic acid, reactive oxygen species and reactive aldehyde metabolisms [63]. The expression and activity of these enzymes have been used, together with other biomarkers, for the identification of CSCs in different types of cancers. For instance, breast cancer stem cells are identified using specific antibodies for CD44 (cluster of differentiation 44) and CD24 (cluster of differentiation 24), and an ADELFLUOR assay to detect ALDH activity. CD44+/CD24−/ALDH+ populations have been shown to possess characteristics of stem cells such as self-renewal, high proliferative potential, clonogenicity and multipotency [67–70]. In summary, ALDHs are associated with CSCs-mediated chemoresistance; however, their mechanisms of action are not well known. Thus, determining their modes of action will certainly help develop better targeting of these enzymes to prevent chemoresistance.

3.4. Resistance to Apoptosis

CSCs have been shown to resist apoptosis mediated by the intrinsic or mitochondria-dependent death pathway, and by the extrinsic cell death receptors pathway [71]. For instance, human glioma and
leukaemia CSCs express lower levels of Fas and Fas ligand (Fas-L) resulting in resistance to extrinsic receptor-mediated cell death [72–77]. CSCs have also been shown to express higher levels of apoptotic inhibitors. The cellular Fas-associated death domain-like IL-1β-converting enzyme (FLICE)-inhibitory protein (c-FLIP) is highly expressed in leukaemia stem cells, and breast and glioblastoma CSCs [78–80]. C-FLIP averts apoptosis by preventing the formation of DISC (death-inducing signaling complex) and consequent activation of the caspase cascade via its interaction with FADD (Fas-associated death domain), caspase-8 or 10 and DR5 (Death receptor 5) [81,82]. Beside the extrinsic apoptotic pathway, the pro-survival protein Bcl-2 that is involved in the mitochondria-dependent death pathway, via its inhibitory interactions with the proapoptotic Bax (Bcl-2-associated x) and Bak (Bcl-2 antagonist killer), was found overexpressed in leukaemia, glioma and glioblastoma stem cells [83–85]. In summary, the inactivation of intrinsic and extrinsic cell death pathways ensures a selective survival advantage for CSCs.

3.5. DNA Repair Response

Another survival advantage in stressful conditions is related to CSCs’ capacity to timely activate the DNA damage sensor and repair machinery [86]. This process involves DNA repair pathways that include the nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), direct repair, and the double-strand break (DSB) recombinational repair. Evidence of CSCs’ resistance to radiotherapy was provided by a study that demonstrated the capacity of glioblastoma stem cells to efficiently activate the ATM serine/threonine kinase (ATM) and the DNA damage checkpoint protein kinase (Chk1) in response to ionising radiations [87]. Another study established the capacity of non-small cell lung cancer (NSCLC) stem cells to resist treatment with chemotherapeutic drugs by activating the Chk1 [88]. Mammosphere cells from the MCF-7 breast cancer cell line have been shown to have lower reactive oxygen species and a more active DNA single-strand break repair (SSBR) pathway, potentially associated to a higher level of expression of the key SSBR protein, human AP endonuclease 1 (Ape1) [89]. In conclusion, the enhanced DNA damage repair exhibited by CSCs appears to protect them from chemotherapy and radiotherapy-mediated apoptosis and adds another layer of protection to their survival capacities. Therefore, a better understanding of the mechanisms involved in DNA repair response will significantly contribute to improved therapy response and clinical outcome of patients treated with radiotherapy and DNA-targeting chemotherapies.

4. CSC Microenvironment

Stem cell niches represent areas of tissue that provide specific microenvironments, which maintain and promote CSCs’ capacity to self-renew and to generate differentiated progenies [90]. The concept of stem cell niche was first formulated by Schofield who demonstrated that successful transplants could only be successful if harvested from the bone marrow [91,92]. He also proposed that the stem cell niche is required for determining stem cell fate, as the behaviour of stem cells is influenced by their association with other cells within the niche. This concept was validated by other groups studying different tissues from invertebrate and vertebrate models [93,94]. This concept is applicable to cancer stem cells where the interaction with these niches is necessary for the maintenance of CSC populations. The CSC microenvironment is a highly heterogeneous complex comprised of cells such as stromal cells, immune cells and epithelial cells, and a network of extracellular macromolecules which provides support for the cells within the extracellular matrix (EC) (Figure 2) [95–97]. The cells found in the niche promote the growth, maintenance and differentiation of cancer stem cells. Currently, cancer therapies have been less successful as most of these drugs target the Bulk population of cancer cells, leaving cancer stem cell populations unaffected [98,99]. Therefore, understanding the relationship between CSCs and their microenvironment could help develop more efficient strategies to eliminate CSCs.
where they contribute to metastasis by secreting TGF-β which enhances tumour proliferation, invasion and metastasis [103]. For instance, tumour-associated macrophages (TAMs) and immune cells (tumour associated macrophages (TAMs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs) and T-helper cells (Th17)). These cells secrete different cytokines and growth factors that promote tumourigenesis, tumour progression and immunosuppression.

4.1. Cancer-Associated Fibroblasts (CAFs)

Although CAFs provide a mechanical supportive role for CSCs via enhanced production of fibrillary collagen, these cells also secrete the cytokine CXCL12 (C-X-C motif chemokine ligand 12) and growth factors such as the hepatocyte growth factor (HGF), the vascular endothelial growth factor (VEGF) and the platelet-derived growth factor (PDGF), which significantly contribute to CSCs’ increased proliferation, invasion and metastasis [97,100,101]. CAFs are also involved in cellular heterogenicity through secreted TGF-β1 (transforming growth factor beta 1), which promotes CSC related epithelial-mesenchymal transition (EMT), an early step of the invasive and metastatic process [102].

4.2. Immune Cells

Several immune cells contribute to the chronic inflammatory status of the CSC microenvironment, which enhances tumour proliferation, invasion and metastasis [103]. For instance, tumour-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) secrete transforming growth factor beta (TGF-β), which contributes to EMT, invasion and metastasis [104–107]. In addition, immune cells within the microenvironment enhance tumour evasion via a variety of mechanisms. TAMs, via secreted TGFβ, recruit Tregs within the niche and contribute to immunosuppression. In a similar fashion, MDSCs, which secrete growth factors such as TGFβ, and cytokines recruit T helper 17 cells to promote their immunosuppressive activity [108]. Although we provide a very brief description here of the role of immune cells within the tumour microenvironment, a deeper discussion of their roles in this context is beyond the scope of the review.

4.3. Mesenchymal Stem Cells (MSCs)

MSCs are multipotent stromal cells that can differentiate into various cell types such as osteocytes, adipocytes and chondrocytes. These cells can migrate to chronic inflammatory sites such as cancer, where they contribute to metastasis by secreting TGFβ which promotes EMT [109]. An involvement in the colonisation process of secondary cancer sites has also been reported for metastatic breast, prostate and lung cancers [110–113]. MSCs have been shown to promote gastric cancer proliferation and
angiogenesis via the secretion of VEGF, macrophage inflammatory protein-2 (MIP-2), TGF-β1, and the pro-inflammatory cytokines interleukin IL-6 and IL-8 [114]. Finally, MSCs may originate CAFs, which further contribute to CSC microenvironment cell heterogenicity and its metastatic potential [115–117].

4.4. Endothelial Cells

Angiogenesis is key for the CSC microenvironment as it delivers nutrients for CSC metabolism that are necessary for their self-renewal, and invasive and metastatic abilities. Through tumour vessels, immune cells such as T regulatory cells (Tregs) are recruited in situ and contribute to immune suppression [118]. Endothelial cells, together with perivascular cells, are the building blocks of vessels, and are stimulated by angiogenic factors such as the vascular endothelial growth factor (VEGF) and within a hypoxic environment such as cancer. This results in increased tumour vasculature and enhanced tumour growth and metastasis [119]. Additionally, tumour endothelial cells have been shown to secrete cytokines such as IL-3, granulocyte-CSF, granulocyte-macrophage-CSF (GM-CSF), IL-1, IL-6, VEGF-A, and bFGF, which promote and maintain CSC self-renewal and CSC-mediated progression [120,121].

5. Cancer Stemness, EMT and Tumour Progression

The main interest in investigating CSCs is related to their capacity to resist chemotherapy and radiotherapy, which results in cancer recurrence that is extremely difficult to overcome using currently available therapies. CSCs can re-initiate the tumorigenic process by generating a new tumour via their self-renewal and generation of differentiated cancer progenies. Another important property is their high invasive and metastatic potential, which involves a cellular process named EMT. Epithelial cells are connected to each other via lateral cell-cell junctions that include desmosomes, adherens junctions, tight junctions and gap junctions. During EMT, epithelial cells begin to trans-differentiate and start losing their lateral junctions and express molecules associated with the mesenchymal phenotype, resulting in the generation of mesenchymal cells [122]. These later play an essential role in the invasion process of adjacent tissues and distant organs via metastasis. The cytokine TGFβ, which is secreted in the CSC microenvironment by MSCs, CAFs and immune cells such as TAMs and MDSCs, plays an essential role in EMT-mediated CSC invasion [123]. TGF-β binding to its receptors results in the activation of the SMAD (small and mothers against decapentaplegic) proteins that translocate to the nucleus and activate target genes involved in EMT such as SNAIL, bHLH and ZEB factors [124,125]. These pro-EMT factors promote the expression of mesenchymal proteins such as N-cadherin, fibronectin and metalloproteinases (MMPs) [123]. Beside the TGFβ signalling, other signalling pathways, such as the WNT (wingless-related integration site), Notch (neurogenic locus notch homolog) and Hedgehog (HH) pathways, also participate in EMT. WNT signalling promotes EMT by stabilising β-catenin through the inhibition of glycogen synthase kinase-3β (GSK3β), resulting in β-catenin translocation to the nucleus and activation of the transcription factors lymphoid enhancer-binding factor 1 (LEF) and T cell factor (TCF), thus promoting a gene expression programme that favours EMT [126]. SHH signalling increases SNAIL1 expression in epithelial cancers leading to increased EMT and invasion [127]. Notch signalling may promote EMT through the Notch intracellular domain that directly activates SNAIL2 expression [128]. Finally, a crosstalk between TGFβ, WNT, Notch, Hedgehog (HH) and other signalling pathways such as RTK (receptor tyrosine kinase) signalling pathways may take place to promote EMT and invasion within the tumour microenvironment [129–131]. In summary, several pathways are involved in regulating EMT, and their targeting may require combination therapies that are directed against different components of this complex network, and with limited toxic effects.

6. CSC Metabolism

Cells require energy to perform their own processes of growth, division and survival. This need is met by the glycolysis metabolic pathway that converts glucose into pyruvate, two energy molecules of ATP and one of NADH (nicotinamide adenine dinucleotide hydrogen) [132]. The pyruvate is later
transported in the mitochondria where it is converted into Acetyl-coA. The coenzyme produces the energy molecules NADH and FADH2 (flavin adenine dinucleotide hydrogen 2) through the Krebs cycle, which is also called the tricarboxylic acid cycle. The hydrogen ions that are used for the electron transport chain via the process of oxidative phosphorylation (OXPHOS) generate 36 molecules of ATPs. CSCs have been shown to have higher glycolytic metabolism when compared to normal and cancer cells. This difference could be due to higher expression of glycolytic enzymes such as GLUT1 (glucose transporter 1), HK-1 (Hexokinase-1) and PDK-1 (Pyruvate Dehydrogenase Kinase 1), and a higher consumption of glucose [132–134]. However, several studies challenged the concept of CSCs’ preferential reliance on the glycolytic metabolism pathway for energy production. These studies suggested that OXPHOS is more likely to be the main source of ATP due to increased mitochondrial ROS (reactive oxygen species), higher rates of oxygen consumption, and overall increase in mitochondrial function [135–141]. Overall, these opposing results could be explained by heterogenous differences in tissue origins, metabolic phenotypes and CSC adaptivity to environmental changes [142]. Therefore, until there is a better understanding of CSC metabolisms, developing targeted therapies remains a future therapeutic possibility.

7. Targeting Strategies of CSCs

CSCs are identified and isolated using cell markers whose expression create tissue-specific signatures. While some markers are commonly expressed by different types of cancer, others are tissue specific (Table 1). In this part, we provide an overview of the different approaches that were clinically employed to target CSCs and the results, so far, of past and ongoing clinical trials (Table 2).

| Table 2. Clinically tested strategies that were employed to target CSCs. Two main therapies were used: monoclonal antibodies therapies and dendritic cells-based vaccines. |
|-----------------|-----------------|-----------------|-----------------|
| Target          | Tumour Type     | Therapy         | Clinical Trial/Reports | Results          |
| CD133            | Advanced cholangiosarcoma | Cocktail CD133 CAR-T and CART-EGFR | NCT02541370 (Phase I and II) | Toxicity         |
|                  | Glioblastoma multiforme | ICT-121 DC vaccine | NCT02049489 (Phase I) | Not published    |
| CD44             | Refractory Acute Myeloid Leukemia | Monoclonal antibody (RG7356) | 146 | Limited clinical activity |
|                  | Metastatic colorectal cancer | Edrecolomab (Monoclonal antibody) | 151 | Limited response |
| EpCAM            | 3622W94 (Monoclonal antibody) | 152 | Toxicity |
|                  | ING-1 (Monoclonal antibody) | Toxicity |
|                  | Adecatumumab (Monoclonal antibody) | 153 | Favourable response in patients with highest expression |
| Various types of tumours | EPCAM-targeted CAR-T cells | NCT02729493 (N/A) | Ongoing |
|                  | NCT02725125 (N/A) | Ongoing |
|                  | NCT02915445 (Phase I) | Ongoing |
|                  | NCT03013712 (Phase I and II) | Ongoing |
7.1. Targeting Cell Surface Biomarkers of CSCs

7.1.1. CD133

CD133 (cluster of differentiation 133 or human prominin-1), a marker that was first identified on the cell surface of CD34+ hematopoietic stem cells [143], has also been used to isolate populations of CSCs from glioblastoma, prostate, pancreas, ovarian, colon, lung and liver cancer (Table 1). The therapeutic targeting potential of CD133 was evaluated for advanced cholangiosarcoma, in a phase 2 clinical trial (NCT02541370) (CCA), and using an immunotherapeutic approach based on CAR-T cells (chimeric antigen receptor T cells) that were transduced with the anti-CD133 (CD133 CAR-T) and anti-EGFR (epidermal growth factor receptor) (CART-EGFR). Although the authors suggested that CART cocktail immunotherapy (CD133 CART and CART-EGFR) may be feasible for the treatment of CCA and other solid malignancies, resolving limitations that are associated with toxicities would need further investigation (Table 2) [144].

7.1.2. CD44

CD44 is a cell surface adhesion receptor that is expressed by several types of cancers. The function of CD44 in growth and migration is dependent on its interaction with different ligands such as hyaluronic acid (HA), osteopontin (OPN), collagens and metalloproteases (MMPs) [145]. Targeting strategies for CD44 have led to the development of an antibody-based therapy that was clinically tested in a phase I study and on patients with refractory AML (acute myeloic leukaemia). The therapy using the humanised monoclonal antibody RG7356 resulted in limited clinical activity; however, the study validates the safety of the clinical use of the drug and suggests testing a combination therapy with other available drugs such as cytarabine (Table 2) [146].

7.1.3. EpCAM

The epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that is expressed by most human carcinomas [147]. The first EpCAM monoclonal antibody (edrecolomab) was tested in patients with metastatic colorectal cancer or in adjuvant settings and had a limited response in a defined number of patients with metastatic disease [148,149]. Unfortunately, subsequent larger studies could not confirm edrecolomab’s clinical activity in the adjuvant setting [150,151]. Other antibodies that were developed such as 3622W94 and ING-1 were discontinued in clinical trials due to poor tolerability (Table 2) [152]. Adecatumumab, a recombinant human IgG1 monoclonal, that was clinically tested in patients with metastatic breast cancer, resulted in a more favourable response in patients with

---

### Table 2. Cont.

| Target       | Tumour Type                                      | Therapy                          | Clinical Trial/Reports | Results         |
|--------------|--------------------------------------------------|----------------------------------|------------------------|-----------------|
| CD47         | Various solid tumours and hematological malignancies | Hu5F9-G4 (Monoclonal antibody)   | NCT02216409 (Phase I)  | Not statistically significant |
|              |                                                  | Combination Hu5F9-G4 and Cetuximab | NCT02953782 (Phase I and II) | Ongoing          |
|              |                                                  | Combination Hu5F9-G4 and Retuximab | NCT02953509 (Phase I and II) | Ongoing          |
|              |                                                  | CC-90002 (Monoclonal antibody)    | NCT02641002 (Phase I)   | Ongoing          |
|              |                                                  | Combination CC-90002 and Retuximab | NCT02367196 (Phase I)   | Ongoing          |
| Autogenic glioma stem-like cells (A2B5+) | Glioblastoma multiforme | Dendritic cell-based vaccine | NCT01567202 (Phase II) | Ongoing          |
higher expression of EpCAM compared to patients who had lower expression on their cell surface (Table 2) [153].

7.1.4. CD47

The integrin associated protein (IAP) or CD47 (cluster of differentiation 47) was first identified as a β3 integrin interacting partner and was later found to interact with trombospondin-1 (TSP-1) and signal regulatory protein-alpha (SIRPα). Through these interactions, CD47 is involved in the regulation of various cellular functions such as cell migration, axon extension, cytokine production and T cell activation [154–158]. CD47 is overexpressed in most cancer types and was shown to promote cancer cell invasion and metastasis [159–167]. Two monoclonal antibodies have been developed to directly target CD47 in different types of cancer and were clinically tested as monotherapy or in combination with other monoclonal antibodies such as cetuximab and rituximab (Table 2) [168–171]. The first humanised anti-CD47 monoclonal antibody, Hu5F9-G4, was administered to patients with various solid tumours in a phase I clinical trial (NCT02216409). The trial aimed at optimising the dosage, the pharmacodynamic and the pharmacokinetic of the administered antibody. Although promising, the results were not statistically significant, and another clinical trial was performed with results not yet available (NCT02678338). The other monoclonal anti-CD47 monoclonal antibody CC-90002 was administered to patients with leukemia and myeloid and acute myelodysplastic syndromes in a phase I clinical trial, and the results are not yet published (NCT02641002). Both Hu5F9-G4 and CC-90002 are being clinically tested in combination therapies with the anti-EGFR antibody (cetuximab) or the anti-CD20 (cluster of differentiation 20) monoclonal antibody for the treatment of solid and haematological malignancies, and the trials are still ongoing (NCT02953782, NCT02953509, NCT02367196) (Table 2).

7.2. Dendritic Cell-Based Vaccines

Dendritic cells (DCs) are antigen presenting cells that initiate and maintain immune responses through their essential function in anti-cancer immunity [172]. DCs present cancer antigens to effector T-cells, which leads to the targeting and eradication of cancer cells. They can also stimulate immunological memories that control cancer recurrence. These properties favour use in the development of dendritic cell-based immunotherapies [172,173]. Several dendritic cell-based vaccines have been tested in patients with glioblastoma multiforme in phase I and II clinical trials (Table 2). A phase I clinical trial study of a dendritic cell vaccine for newly diagnosed or recurrent glioblastoma patients resulted in adverse events and treatment-related toxicities (NCT02010606). This study used patients own immune-stimulating dendritic cells, which were isolated and treated to promote an immune response against cancer stem cells and injected under the skin in a series of vaccinations. Another phase I study investigated the use of CD133 peptides for a dendritic cell-based vaccine (ICT-121 DC vaccine), which was clinically tested in patients with glioblastoma multiforme (NCT02049489). In this study CD133 peptides were used to load DCs that were injected in patients to elicit an immune response. So far, the results of this study have not been published. An ongoing phase II study investigates the efficacy of autologous dendritic cells (DCs) that were loaded with autogenic glioma stem-like cells (A2B5+) and were administered as a vaccination in adults with glioblastoma multiforme (primary or secondary) (NCT01567202). Finally, EPCAM-targeted CAR-T cells have been generated using genetically modified T cells that express a chimeric antigen receptor (CAR), and that bind to tumour cells expressing the EPCAM protein on the cell surface [174]. These CAR-Ts are being clinically tested in patients and for different types of solid tumours (NCT02729493, NCT02725125, NCT02915445 and NCT03013712).

8. Conclusions

Although progress has been made in developing cancer therapies that target CSCs, the specificity of the targeted antigens remains a challenge. Most of the therapies are directed against biomarkers
that are not specifically expressed by CSCs and that are also found in normal cells within the body. This has unfortunate effects on increasing toxicity in treated patients. For instance, therapies that target CD133 resulted in adverse events and treatment-related toxicities in glioblastoma patients who were treated with a CD133-specific dendritic vaccine (NCT02010606). However, other ongoing therapies such as the ones combining two monoclonal antibodies or using EPCAM as a target may lead to better therapies. Making the data of the clinical trials available to the scientific and clinical communities will certainly help in sharing information for the development of more efficient targeting therapies (NCT02678338, NCT02641002, NCT02729493, NCT02725125, NCT02915445 and NCT03013712). Although cancer bi-therapies are certainly a better choice, further studies are required to identify more specific targets with a much lower toxicity when tested in clinical trials. Large scale analysis of tumour samples from different patients and cohorts using genomics, proteomics and data mining approaches (Bioinformatics) could lead to the identification of CSC-specific genes or antigen signatures that will allow the development of more efficient CSC targeted therapies with lower associated toxicities for treated patients. Furthermore, these approaches could also provide patient specific signatures that will allow a personalised therapy and reduced cost and toxicity.

Another aspect that has not been discussed in this review, is the role of epigenetics in regulating the role of CSCs in cancer initiation and progression. Non-coding RNAs such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) function by regulating the expression of several CSC-specific genes. Other epigenetic regulators involve histone acetyl transferases (HATs) and histone deacetylases, which also play important roles in maintaining CSC stemness and differentiation [175,176]. Therefore, developing therapies, such as gene targeting, nanoparticles-based therapies, and HDAC inhibitors could also constitute a potential way forward for targeting CSCs.

In summary, whether using drugs, immunotherapies or gene therapies, the specificity of the targets is key for a successful eradication of CSCs and cancer recurrence.

**Funding:** This research received no external funding.

**Acknowledgments:** We would like to thank the John and Lucille van Geest Foundation and IMMUTRAIN for supporting this work.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Global Health Observatory (GHO) data. Available online: https://www.who.int/gho/publications/world_health_statistics/2019/en/ (accessed on 01 July 2019).
2. Regad, T. Tissue-specific cancer stem cells: Reality or a mirage? *Transl. Med. Rep.* 2017, 1. [CrossRef]
3. Regad, T.; Sayers, T.J.; Rees, R.C. Principles of Stem Cell Biology and Cancer: Future Applications and Therapeutics; Wiley-Blackwell: Oxford, UK, 2015.
4. Yu, Z.; Pestell, T.G.; Lisanti, M.P.; Pestell, R.G. Cancer stem cells. *Int. J. Biochem. Cell Biol.* 2012, 44, 2144–2151. [CrossRef] [PubMed]
5. Eyler, C.E.; Rich, J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. *J. Clin. Oncol.* 2008, 26, 2839–2845. [CrossRef] [PubMed]
6. Baumann, M.; Krause, M.; Hill, R. Exploring the role of cancer stem cells in radioresistance. *Nat. Rev. Cancer* 2008, 8, 545–554. [CrossRef] [PubMed]
7. Zhao, J. Cancer Stem Cells and Chemoresistance: The Smartest Survives the Raid. *Pharmacol. Ther.* 2016, 160, 145–158. [CrossRef] [PubMed]
8. La Noce, M.; Paino, F.; Mele, L.; Papaccio, G.; Regad, T.; Lombardi, A.; Papaccio, F.; Desiderio, V.; Tirino, V. HDAC2 depletion promotes osteosarcoma’s stemness both in vitro and in vivo: A study on a putative new target for CSCs directed therapy. *J. Exp. Clin. Cancer Res.* 2018, 37, 296. [CrossRef] [PubMed]
9. Takahashi, R.-U.; Miyazaki, H.; Ochiya, T. The role of microRNAs in the regulation of cancer stem cells. *Front. Genet.* 2014, 4, 295. [CrossRef]
10. Oskarsson, T.; Batlle, E.; Massagué, J. Metastatic Stem Cells: Sources, Niches, and Vital Pathways. *Cell Stem Cell* 2014, 14, 306–321. [CrossRef]
11. Voog, J.; Jones, D.L. Stem Cells and the Niche: A Dynamic Duo. *Cell Stem Cell* 2010, 6, 103–115. [CrossRef]  
12. Myron, S. Rudolf Virchow. *Emerg Infect Dis.* 2008, 14, 1480–1481.  
13. Welte, Y.; Adjaye, J.; Lehrach, H.R.; Regenbrecht, C.R. Cancer stem cells in solid tumors: Elusive or illusive? *Cell Commun. Signal.* 2010, 8, 6. [CrossRef] [PubMed]  
14. Bergsagel, D.E.; McCulloch, E.A.; Park, C.H. Mouse Myeloma Tumor Stem Cells: A Primary Cell Culture Assay2. *J. Natl. Cancer Inst.* 1971, 46, 411–422.  
15. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994, 367, 645–648. [CrossRef] [PubMed]  
16. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. *Proc. Natl. Acad. Sci. USA* 2003, 100, 3983–3988. [CrossRef] [PubMed]  
17. Schatton, T.; Murphy, G.F.; Frank, N.Y.; Yamaura, K.; Waaga-Gasser, A.M.; Gasser, M.; Zhan, Q.; Jordan, S.; Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M.; Foster, R.; Buckanovich, R.J.; Rueda, B.R. Ovarian cancer stem cells: Working towards the root of stemness. *Cancer Cell* 2007, 14, 153–166. [CrossRef] [PubMed]  
18. Kumar, D.; Gorain, M.; Kundu, G.; Kundu, G.C. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma. *Mol. Cancer* 2017, 16, 7. [CrossRef] [PubMed]  
19. Mathieu, M.G.; Miles, A.K.; Ahmad, M.; Buczek, M.E.; Pockley, A.G.; Rees, R.C.; Regad, T. The helicase HAGE prevents interferon-alpha-induced PML expression in ABCBS+ malignant melanoma-initiating cells by promoting the expression of SOCS1. *Cell Death Disease* 2014, 5, e1061. [CrossRef] [PubMed]  
20. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in human brain tumors. *Cancer Res.* 2003, 63, 5821–5828.  
21. Ricci-Vitiani, L.; Lombardi, D.G.; PiloZZI, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. *Nature* 2007, 445, 111–115. [CrossRef] [PubMed]  
22. Dalerba, P.; Dylla, S.J.; Park, I.K.; Liu, R.; Wang, X.; Cho, R.W.; Hoey, T.; Gurney, A.; Huang, E.H.; Simeone, D.M.; et al. Phenotypic characterization of human colorectal cancer stem cells. *Proc. Natl. Acad. Sci. USA* 2007, 104, 10158–10163. [CrossRef] [PubMed]  
23. Yeung, T.M.; Gandhi, S.C.; Wilding, J.L.; Muschel, R.; Bodmer, W.F. Cancer stem cells from colorectal cancer-derived cell lines. *Proc. Natl. Acad. Sci. USA* 2010, 107, 3722–3727. [CrossRef] [PubMed]  
24. Vermeulen, L.; Todaro, M.; de Sousa Mello, F.; Sprick, M.R.; Kemper, K.; Perez Alea, M.; Richel, D.J.; Stassi, G.; Medema, J.P. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. *Proc. Natl. Acad. Sci. USA* 2008, 105, 13427–13432. [CrossRef] [PubMed]  
25. Bekaii-Saab, T.; El-Rayes, B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. *Cancer* 2017, 123, 1301–1312. [CrossRef] [PubMed]  
26. Singh, S.R. Gastric cancer stem cells: A novel therapeutic target. *Cancer Lett.* 2013, 338, 110–119. [CrossRef] [PubMed]  
27. Chinn, S.B.; Darr, O.A.; Owen, J.H.; Bellile, E.; McHugh, J.B.; Specter, M.E.; Papagerakis, S.M.; Chepeha, D.B.; Bradford, C.R.; Carey, T.E.; et al. Cancer stem cells: Mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. *Head Neck* 2015, 37, 317–326. [CrossRef] [PubMed]  
28. Foster, R.; Buckanovich, R.J.; Rueda, B.R. Ovarian cancer stem cells: Working towards the root of stemness. *Cancer Lett.* 2013, 338, 147–157. [CrossRef]  
29. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M.; Lepelletier, Y.; et al. Identification of Pancreatic Cancer Stem Cells. *Cancer Res.* 2007, 67, 1030–1037. [CrossRef]  
30. Hou, Y.; Zou, Q.; Ge, R.; Shen, F.; Wang, Y. The critical role of CD133 (+) CD44(+)/high) tumor cells in hematogenous metastasis of liver cancers. *Cell Res.* 2012, 22, 259–272. [CrossRef]  
31. Yang, Z.F.; Ho, D.W.; Ng, M.N.; Lau, C.K.; Yu, W.C.; Ngai, P.; Chu, P.W.; Lam, C.T.; Poon, R.T.; Fan, S.T. Significance of CD90+ cancer stem cells in human liver cancer. *Cancer Cell* 2008, 13, 153–166. [CrossRef] [PubMed]  
32. Kimura, O.; Takahashi, T.; Ishii, N.; Inoue, Y.; Ueno, Y.; Kogure, T.; Fukushima, K.; Shina, M.; Yamagiwa, Y.; Kondo, Y.; et al. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. *Cancer Sci.* 2010, 101, 2145–2155. [CrossRef]  
33. Haraguchi, N.; Ishii, H.; Mimori, K.; Tanaka, F.; Ohkuma, M.; Kim, H.M.; Akita, H.; Takiuchi, D.; Hatano, H.; Nagano, H.; et al. CD13 is a therapeutic target in human liver cancer stem cells. *J. Clin. Investig.* 2010, 120, 3326–3339. [CrossRef] [PubMed]
34. Chen, X.; Li, Q.; Liu, X.; Liu, C.; Liu, R.; Rycaj, K.; Zhang, D.; Liu, B.; Jeter, C.; Calhoun-Davis, T.; et al. Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer (CRPC). *Clin. Cancer Res.* 2016, 22, 4505–4516. [CrossRef] [PubMed]

35. MacDonagh, L.; Gray, S.G.; Breen, E.; Cuffe, S.; Finn, S.P.; O’Byrne, K.J.; Barr, M.P. Lung cancer stem cells: The root of resistance. *Cancer Lett.* 2016, 372, 147–156. [CrossRef] [PubMed]

36. Shackleton, M.; Quintana, E.; Fearon, E.R.; Morrison, S.J. Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution. *Cell* 2009, 138, 822–829. [CrossRef] [PubMed]

37. Batlle, E.; Clevers, H. Cancer stem cells revisited. *Nat. Med.* 2017, 23, 1124–1134. [CrossRef] [PubMed]

38. Rich, J.N. Cancer stem cells: Understanding tumor hierarchy and heterogeneity. *Medicine* 2016, 95, S2–S7. [CrossRef] [PubMed]

39. Gottesman, M.M.; Lavi, O.; Hall, M.D.; Gillet, J.-P. Towards a Better Understanding of the Complexity of Cancer Drug Resistance. *Annu. Rev. Pharmacol. Toxicol.* 2016, 56, 85–102. [CrossRef]

40. Hemmati, H.D.; Nakano, I.; Lazareff, J.A.; Masterman-Smith, M.; Geschwind, D.H.; Bronner-Fraser, M.; Kornblum, H.I. Cancerous stem cells can arise from pediatric brain tumors. *Proc. Natl. Acad. Sci. USA* 2003, 100, 15178–15183. [CrossRef]

41. Fang, D.; Nguyen, T.K.; Finko, R.; Kulp, A.N.; Hotz, S.; Van Belle, P.A.; Xu, X.; Elder, D.E.; Herlyn, M.; et al. A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas. *Cancer Res.* 2005, 65, 9328–9337. [CrossRef]

42. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective Identification of Tumorigenic Prostate Cancer Stem Cells. *Cancer Res.* 2005, 65, 10946–10951. [CrossRef]

43. Bapat, S.A.; Mali, A.M.; Koppikar, C.B.; Kurrey, N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. *Cancer Res.* 2005, 65, 3025–3029. [CrossRef] [PubMed]

44. Saikawa. Tumor initiating potential of side population cells in human gastric cancer. *Int. J. Oncol.* 2009, 34, 1201–1207. [CrossRef]

45. Ho, M.M.; Ng, A.V.; Lam, S.; Hung, J.Y. Side Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-like Cancer Cells. *Cancer Res.* 2007, 67, 4827–4833. [CrossRef] [PubMed]

46. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. *Cell Stem Cell* 2007, 1, 313–323. [CrossRef] [PubMed]

47. Curtis, S.J.; Sinkevicius, K.W.; Li, D.; Lau, A.N.; Roach, R.R.; Zamponi, R.; Woolfenden, A.E.; Kirsch, D.G.; Wong, K-K.; Kim, C.F. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. *Cell Stem Cell* 2010, 7, 127–133. [CrossRef] [PubMed]

48. Clarkson, B.; Strife, A.; Fried, J.; Sakai, Y.; Ota, K.; Okhita, T.; Masuda, R. Studies of cellular proliferation in human leukemia. IV. Behavior of normal hematopoietic cells in 3 adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days. *Cancer* 1970, 26, 1–19. [CrossRef]

49. Moore, N.; Houghton, J.; Lyle, S. Slow-Cycling Therapy-Resistant Cancer Cells. *Stem Cells Dev.* 2012, 21, 1822–1830. [CrossRef]

50. Vidal, S.J.; Rodriguez-Bravo, V.; Galsky, M.; Cordon-Cardo, C.; Domingo-Domenech, J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. *Oncogene* 2013, 33, 4451–4463. [CrossRef]

51. Ajani, J.A.; Song, S.; Hochster, H.S.; Steinberg, I.B. Cancer Stem Cells: The Promise and the Potential. *Semin. Oncol.* 2015, 42, S3–S17. [CrossRef]

52. Abdullah, L.N.; Chow, E.K.-H. Mechanisms of chemoresistance in cancer stem cells. *Clin. Transl. Med.* 2013, 2, 3. [CrossRef]

53. Begicicic, R.-R.; Falasca, M. ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. *Int. J. Mol. Sci.* 2017, 18, 2362. [CrossRef]

54. Kolenda, J.; Jensen, S.S.; Aaberg-Jessen, C.; Christensen, K.; Andersen, C.; Brünner, N.; Kristensen, B.W. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. *J. Neuro-Oncol.* 2010, 103, 43–58. [CrossRef]

55. Deeley, R.G.; Cole, S.P. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). *FEBS Lett.* 2005, 580, 1103–1111. [CrossRef]
56. Zhou, S.-F.; Wang, L.-L.; Di, Y.M.; Xue, C.C.; Duan, W.; Li, C.G.; Li, Y. Substrates and inhibitors of human multirud drug resistance associated proteins and the implications in drug development. *Curr. Med. Chem.* **2008**, *15*, 1981–2039. [CrossRef]
57. Shaffer, B.C.; Gillet, J.-P.; Patel, C.; Baer, M.R.; Bates, S.E.; Gottesman, M.M. Drug resistance: Still a daunting challenge to the successful treatment of AML. *Drug Resist. Updat.* **2012**, *15*, 62–69. [CrossRef]
58. Xi, G.; Hayes, E.; Lewis, R.; Ichi, S.; Mania-Farnell, B.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C.S.; Tomita, T. CD133 and DNA-PK regulate MDRI via the PI3K- or Akt-NF-κB pathway in multirud-resistant glioblastoma cells in vitro. *Oncogene* **2015**, *35*, 241–250. [CrossRef]
59. Huang, B.; Fu, S.J.; Fan, W.Z.; Wang, Z.H.; Chen, Z.B.; Guo, S.J.; Chen, J.X.; Qiu, S.P. PKC inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. *Cancer Lett.* **2016**, *376*, 148–154. [CrossRef]
60. Johnson, R.A.; Shepard, E.M.; Scotto, K.W. Differential Regulation of MDRI Transcription by the p53 Family Members. *J. Biol. Chem.* **2005**, *280*, 13213–13219. [CrossRef]
61. Chou, J.-L.; Huang, R.-L.; Shay, J.; Chen, L.-Y.; Lin, S.-J.; Yan, P.S.; Chao, W.-T.; Lai, Y.-H.; Lai, Y.-L.; Chao, T.-K.; et al. Hypermethylation of the TGF-β target, ABCA1 is associated with poor prognosis in ovarian cancer patients. *Clin. Epigenet.* **2015**, *7*, 1. [CrossRef]
62. Sládek, N.E. Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact. *J. Biochem. Mol. Toxicol.* **2003**, *17*, 7–23. [CrossRef]
63. Ikawa, M.; Impraim, C.C.; Wang, G.; Yoshida, A. Isolation and characterization of aldehyde dehydrogenase isozymes from usual and atypical human livers. *J. Biol. Chem.* **1983**, *258*, 6282–6287.
64. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* **2007**, *1*, 555–567. [CrossRef]
65. Fitzgerald, T.L.; Rangan, S.; Dobbs, L.; Starr, S.; Sigionas, G. The impact of Aldehyde dehydrogenase 1 expression on prognosis for metastatic colon cancer. *J. Surg. Res.* **2014**, *192*, 82–89. [CrossRef]
66. Vogler, T.; Kriegl, L.; Horst, D.; Engel, J.; Sagebiel, S.; Schäffer, A.J.; Kirchner, T.; Jung, A. The expression pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent prognostic marker for low survival in colorectal tumors. *Exp. Mol. Pathol.* **2012**, *92*, 111–117. [CrossRef]
67. Deng, L.; Zhou, J.-F.; Sellers, R.S.; Li, J.-F.; Nguyen, A.V.; Wang, Y.; Orlofsky, A.; Liu, Q.; Hume, D.A.; Pollard, J.W.; et al. A Novel Mouse Model of Inflammatory Bowel Disease Links Mammalian Target of Rapamycin-Dependent Hyperproliferation of Colonic Epithelium to Inflammation-Associated Tumorigenesis. *Am. J. Pathol.* **2010**, *176*, 952–967. [CrossRef]
68. Hessman, C.J.; Bubbers, E.J.; Billingsley, K.G.; Herzog, D.O.; Wong, M.H. Loss of expression of the cancer stem cell marker aldehyde dehydrogenase1 correlates with advanced stage colorectal cancer. *Am. J. Surg.* **2012**, *203*, 649–653. [CrossRef]
69. Kim, M.P.; Fleming, J.B.; Wang, H.; Abbuzzese, J.L.; Choi, W.; Kopetz, S.; McConkey, D.J.; Evans, D.B.; Gallick, G.E. ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. *PLoS ONE* **2011**, *6*, e20636. [CrossRef]
70. Li, T.; Su, Y.; Mei, Y.; Leng, Q.; Leng, B.; Liu, Z.; Stass, S.A.; Jiang, F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. *Lab. Invest.* **2009**, *90*, 234–244. [CrossRef]
71. Wang, Y.-H.; Scadden, D.T. Harnessing the apoptotic programs in cancer stem-like cells. *EMBO Rep.* **2015**, *16*, 1084–1096. [CrossRef]
72. Costello, R.T.; Mallet, F.; Chambost, H.; Sianty, D.; Arnoulet, C.; Gastaut, J.A.; Olive, D. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): Reduced immunogenicity and high frequency of CD34+/CD38– leukemic progenitors. *Leukemia* **1999**, *13*, 1513–1518. [CrossRef]
73. Peller, M.; Frei, K.; Groscurth, P.; Kranner, P.H.; Yonekawa, Y.; Fontana, A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. *J. Clin. Invest.* **1994**, *94*, 954–964. [CrossRef]
74. Frei, K.; Ambar, B.; Adam, N.; Yonekawa, Y.; Fontana, A. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis. *J. Neuroimmunol.* **1998**, *87*, 105–113. [CrossRef]
75. Tao, J.; Qiu, B.; Zhang, D.; Wang, Y. Expression levels of Fas/Fas-L mRNA in human brain glioma stem cells. *Mol. Med. Rep.* **2012**, *5*, 1202–1206. [CrossRef]
76. Eisele, G.; Roth, P.; Hasenbach, K.; Aulwurm, S.; Wolpert, F.; Tabatabai, G.; Wick, W.; Weller, M. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. *Neuro-Oncology* 2010, 13, 155–164. [CrossRef]

77. Eisele, G.; Wolpert, F.; Decrey, G.; Weller, M. APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. *Anticancer Res.* 2013, 33, 3563–3571.

78. Zobalova, R.; McDermott, L.; Stantic, M.; Prokopova, K.; Dong, L.-F.; Neuzil, J. CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. *Biochem. Biophys. Res. Commun.* 2008, 373, 567–571. [CrossRef]

79. Dong, L.-F.; Freeman, R.; Liu, J.; Zobalova, R.; Marin-Hernandez, A.; Stantic, M.; Butcher, B.; et al. Suppression of Tumor Growth In vivo by the Mitocan α-tocopheryl Succinate Requires Respiratory Complex II. *Clin. Cancer Res.* 2009, 15, 1593–1600. [CrossRef]

80. Ding, L.; Yuan, C.; Wei, F.; Wang, G.; Zhang, J.; Bellail, A.C.; Zhang, Z.; Olson, J.J.; Hao, C. Cisplatin Restores TRAIL apoptotic pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP. *Cancer Investig.* 2011, 29, 511–520. [CrossRef]

81. Dutton, A.; Young, L.S.; Murray, P.G. The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. *Expert Opin. Ther. Targets* 2006, 10, 27–35. [CrossRef]

82. Shirley, S.; Micheau, O. Targeting c-FLIP in cancer. *Cancer Lett.* 2013, 332, 141–150. [CrossRef]

83. Lauria, F.; Raspadori, D.; Rondelli, D.; Ventura, M.; Fiacchini, M.; Visani, G.; Forconi, F.; Tura, S. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. *Leukemia* 1997, 11, 2075–2078. [CrossRef]

84. Campos, L.; Oriol, P.; Sabido, O.; Guyotat, D. Simultaneous Expression of P-Glycoprotein and BCL-2 in Acute Myeloid Leukemia Blast Cells. *Leuk. Lymphoma* 1997, 27, 119–125. [CrossRef]

85. Tóthová, E.; Kafková, A.; Stecová, N.; Fricoň, M.; Guman, T.; Svorcová, E. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. *Neoplasma* 2002, 49, 91–94.

86. Maugeri-Saccó, M.; Bartucci, M.; De Maria, R. DNA Damage Repair Pathways in Cancer Stem Cells. *Mol. Cancer Ther.* 2012, 11, 1627–1636. [CrossRef]

87. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 2006, 444, 756–760. [CrossRef]

88. Bartucci, M.; Svensson, S.; Romania, P.; Dattilo, R.; Patrizii, M.; Signore, M.; Navarra, S.; Lotti, F.; Biffoni, M.; Pilozzi, E.; et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. *Cell Death Differ.* 2011, 19, 768–778. [CrossRef]

89. Karimi-Busheri, F.; Rasouli-Nia, A.; Mackey, J.R.; Weinfeld, M. Senescence evasion by MCF-7 human breast tumor-initiating cells. *Breast Cancer Res.* 2010, 12, R31. [CrossRef]

90. Morrison, S.J.; Spradling, A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. *Cell* 2008, 132, 598–611. [CrossRef]

91. Schofield, R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. *Blood Cells* 1978, 4, 7–25.

92. Rashi, N.M.; Lo Celso, C. Flying back to the nest: Intravital microscopy reveals how the niche can induce stemness. *Intravital* 2014, 3, e29653. [CrossRef]

93. Ferraro, F.; Celsa, C.L.; Scadden, D. Adult stem cells and their niches. *Single Mol. Single Cell Seq.* 2010, 695, 155–168. [CrossRef]

94. Wu, T.; Dai, Y. Tumor microenvironment and therapeutic response. *Cancer Lett.* 2017, 387, 61–68. [CrossRef]

95. Balkwill, F.; Capasso, M.; Hagemann, T. The tumor microenvironment at a glance. *J. Cell Sci.* 2012, 125, 5591–5596. [CrossRef]

96. Korkaya, H.; Liu, S.; Wicha, M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. *J. Clin. Investig.* 2011, 121, 3804–3809. [CrossRef]

97. Plaks, V.; Kong, N.; Werb, Z. The Cancer Stem Cell Niche: How Essential is the Niche in Regulating Stemness of Tumor Cells? *Cell Stem Cell* 2015, 16, 225–238. [CrossRef]

98. Longley, D.; Johnston, P. Molecular mechanisms of drug resistance. *J. Pathol.* 2005, 205, 275–292. [CrossRef]

99. Prieto-Vila, M.; Takahashi, R.-U.; Usuba, W.; Kohama, I.; Ochiya, T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. *Int. J. Mol. Sci.* 2017, 18, 2574. [CrossRef]
100. Junttila, M.R.; De Sauvage, F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. *Nature 2013*, *501*, 346–354. [CrossRef]
101. Najafi, M.; Farhood, B.; Mortezaei, K. Cancer stem cells (CSCs) in cancer progression and therapy. *J. Cell. Physiol. 2018*, *234*, 8381–8395. [CrossRef]
102. Zhuang, J.; Lu, Q.; Shen, B.; Huang, X.; Shen, L.; Zheng, X.; Huang, R.; Yan, J.; Guo, H. TGFβ1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT. *Sci. Rep. 2015*, *5*, 11924. [CrossRef]
103. Cabarcas, S.M.; Mathews, L.A.; Farrar, W.L. The cancer stem cell niche—there goes the neighborhood? *Int. J. Cancer 2011*, *129*, 2315–2327. [CrossRef]
104. Cabarcas, S.M.; Mathews, L.A.; Farrar, W.L. The cancer stem cell niche—there goes the neighborhood? *Cancer Res. 2013*, *73*, 76–84. [CrossRef]
105. Katsuno, Y.; Lamouille, S.; Derynck, R. TGF-β signaling and epithelial–mesenchymal transition in cancer progression. *Curr. Opin. Oncol. 2013*, *25*, 76–84. [CrossRef]
106. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. *Nat. Rev. Cancer 2006*, *6*, 392–401. [CrossRef]
107. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. *J. Clin. Investig. 2009*, *119*, 1420–1428. [CrossRef]
108. Kitamura, T.; Qian, B.-Z.; Pollard, J.W. Immune cell promotion of metastasis. *Oncogene 2015*, *35*, 3465–3475. [CrossRef]
109. Ridge, S.M.; Sullivan, F.J.; Glynn, S.A. Mesenchymal stem cells: Key players in cancer progression. *Mol. Cancer 2017*, *16*, 31. [CrossRef]
110. Karnoub, A.E.; Dash, A.B.; Vo, A.P.; Sullivan, A.; Brooks, M.W.; Bell, G.W.; Richardson, A.L.; Polyak, K.; Tubo, R.; Weinberg, R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature 2007*, *449*, 557–563. [CrossRef]
111. Corcoran, K.E.; Trzaska, K.A.; Fernandes, H.; Bryan, M.; Taborga, M.; Srinivas, V.; Packman, K.; Patel, P.S.; Rameshwar, P. Mesenchymal Stem Cells in Early Entry of Breast Cancer into Bone Marrow. *PLoS ONE 2008*, *3*, e2563. [CrossRef]
112. Nabha, S.M.; Dos Santos, E.B.; Yamamoto, H.A.; Belizi, A.; Dong, Z.; Meng, H.; Saliganan, A.; Sabbota, A.; Bonfil, R.D.; Cher, M.L. Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. *Int. J. Cancer 2008*, *122*, 2482–2490. [CrossRef]
113. Duda, D.G.; Duyverman, A.M.J.; Kohno, M.; Snuderl, M.; Pockley, A.G.; Rees, R.C.; Hulman, G.; Van Schalkwyk, G.; Parkinson, R.; et al. Cytoplasmic PML promotes TGF-β-associated epithelial–mesenchymal transition and invasion in prostate cancer. *Oncogene 2015*, *35*, 3465–3475. [CrossRef]
114. Li, W.; Zhou, Y.; Yang, J.; Zhang, X.; Zhang, H.; Zhang, T.; Zhao, S.; Zheng, P.; Huo, J.; Wu, H. Gastric cancer-derived mesenchymal stem cells prompt gastric cancer progression through secretion of interleukin-8. *J. Exp. Clin. Cancer Res. 2015*, *34*, 52. [CrossRef]
115. Spaeth, E.L.; Dembinski, J.L.; Sasser, A.K.; Watson, K.; Klopp, A.; Hall, B.; Andreeff, M.; Marini, F. Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression. *PLoS ONE 2009*, *4*, e4992. [CrossRef]
116. Mishra, P.J.; Mishra, P.J.; Humeniuk, R.; Medina, D.J.; Alexe, G.; Mesirov, J.P.; Ganesan, S.; Glod, J.W.; Banerjee, D. Carcinoma Associated Fibroblast Like Differentiation of Human Mesenchymal Stem Cells. *Cancer Res. 2008*, *68*, 4331–4339. [CrossRef]
117. Peng, Y.; Li, Z.; Li, Z. GRP78 secreted by tumor cells stimulates differentiation of bone marrow mesenchymal stem cells to cancer-associated fibroblasts. *Biochem. Biophys. Res. Commun. 2013*, *440*, 558–563. [CrossRef]
118. Hida, K.; Maishi, N.; Annan, D.A.; Hida, Y. Contribution of Tumor Endothelial Cells in Cancer Progression. *Int. J. Mol. Sci. 2018*, *19*, 1272. [CrossRef]
119. Fessler, E.; Borovski, T.; Medema, J.P. Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF. *Mol. Cancer 2015*, *14*, 157. [CrossRef]
120. Pirtskhalashvili, G.; Nelson, J.B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. *Prostate 2000*, *44*, 77–87. [CrossRef]
121. Butler, J.M.; Kobayashi, H.; Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. *Nat. Rev. Cancer 2010*, *10*, 138–146. [CrossRef]
122. Grünert, S.; Jechlinger, M.; Beug, H.; Gruenert, S. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 2003, 4, 657–665. [CrossRef]
123. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [CrossRef]
124. Massague, J. TGFbeta signalling in context. Nature reviews. Mol. Cell Biol. 2012, 13, 616–630. [CrossRef]
125. Thiery, J.P. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442–454. [CrossRef]
126. Niehrs, C. The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 2012, 13, 767–779. [CrossRef]
127. Fendrich, V.; Waldmann, J.; Esni, F.; Ramaswamy, A.; Mullendore, M.; Buchholz, M.; Maitra, A.; Feldmann, G. Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum. Endocr.-Relat. Cancer 2007, 14, 865–874. [CrossRef]
128. Xie, M.; Zhang, L.; He, C.-S.; Xu, F.; Liu, J.-L.; Hu, Z.-H.; Zhao, L.-P.; Tian, Y. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J. Cell. Biochem. 2012, 113, 150–1513. [CrossRef]
129. Shirakihara, T.; Horiguchi, K.; Miyazawa, K.; Ehata, S.; Shibata, T.; Morita, I.; Miyazono, K.; Saitoh, M. TGF-β regulates isoform switching of FGF receptors and epithelial–mesenchymal transition. EMBO J. 2011, 30, 783–795. [CrossRef]
130. Uttamsingh, S.; Bao, X.; Nguyen, K.T.; Bhanot, M.; Gong, J.; Chan, J.L.-K.; Liu, F.; Chu, T.T.; Wang, L.-H. Synergistic effect between EGF and TGF-β1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 2007, 27, 2626–2634. [CrossRef]
131. Wendt, M.K.; Smith, J.A.; Schiemann, W.P. Transforming Growth Factor-β-Induced Epithelial-Mesenchymal Transition Facilities Epidermal Growth Factor-Dependent Breast Cancer Progression. Oncogene 2010, 29, 6485–6498. [CrossRef]
132. Snyder, V.; Reed-Newman, T.C.; Arnold, L.; Thomas, S.M.; Anant, S. Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front. Oncol. 2018, 8, 203. [CrossRef]
133. Emmink, B.L.; Verbeem, A.; Van Houdt, W.J.; Steller, E.J.; Govaert, K.M.; Pham, T.V.; Pierma, S.R.; Rinkes, I.H.B.; Jimenez, C.R.; Krannenburg, O. The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J. Proteom. 2013, 91, 84–96. [CrossRef]
134. Hammoudi, N.; Ahmed, K.B.R.; Garcia-Prieto, C.; Huang, P. Metabolic alterations in cancer cells and therapeutic implications. Chin. J. Cancer 2011, 30, 508–525. [CrossRef]
135. Ye, X.-Q.; Li, Q.; Wang, G.-H.; Sun, F.-F.; Huang, G.-J.; Bian, X.-W.; Yu, S.-C.; Qian, G.-S. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int. J. Cancer 2011, 129, 820–831. [CrossRef]
136. Janiszewska, M.; Suva, M.L.; Riggi, N.; Houtkooper, R.H.; Auwerx, J.; Clément-Schatlo, V.; Radovanic, I.; Rheinbay, E.; Provero, P.; Slamenkovic, I. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012, 26, 1926–1944. [CrossRef]
137. Sancho, P.; Burgos-Ramos, E.; Taverna, A.; Kheir, T.B.; Jagust, P.; Schoenhals, M.; Barneda, D.; Sellers, K.; Campos-Olivas, R.; Graña, O.; et al. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell Metab. 2015, 22, 590–605. [CrossRef]
138. Lagadinou, E.D.; Sach, A.; Callahan, K.; Rossi, R.M.; Neering, S.J.; Minhajuddin, M.; Ashton, J.M.; Pei, S.; Grose, V.; O’Dwyer, K.M.; et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013, 12, 329–341. [CrossRef]
139. Pastò, A.; Bellio, C.; Pilotto, G.; Cinimale, V.; Silic-Benussi, M.; Guzzo, G.; Rasola, A.; Frasson, C.; Nardo, G.; Zulato, E.; et al. Cancer stem cells from epithelial ovarian cancer patients privilege oncophosphorylation. Oncotarget 2014, 5, 4305–4319. [CrossRef]
140. De Luca, A.; Fiorillo, M.; Peiris-Pagès, M.; Oszvari, B.; Smith, D.L.; Sanchez-Alvarez, R.; Martinez-Outschoorn, U.E.; Cappello, A.R.; Pezzi, V.; Lisanti, M.P.; et al. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget 2015, 6, 14777–14795. [CrossRef]
141. Vlashi, E.; Lagadec, C.; Vergnes, L.; Reue, K.; Frohnen, P.; Chan, M.; Alhiyari, Y.; Dratver, M.B.; Pajonk, F. Metabolic differences in breast cancer stem cells and differentiated progeny. Breast Cancer Res. Treat. 2014, 146, 525–534. [CrossRef]
142. Zheng, J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). *Oncol. Lett.* 2012, 4, 1151–1157. [CrossRef]

143. Yin, A.H.; Miraglia, S.; Zanjani, E.D.; Almeida-Porada, G.; Ogawa, M.; Leary, A.G.; Olweus, J.; Kearney, J.; Buck, D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. *Blood* 1997, 90, 5002–5012.

144. Feng, K.-C.; Guo, Y.-L.; Liu, Y.; Dai, H.-R.; Wang, Y.; Lv, H.-Y.; Huang, J.-H.; Yang, Q.-M.; Han, W.-D. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. *J. Hematol. Oncol.* 2017, 10, 4. [CrossRef]

145. Senbanjo, L.T.; Chellaiyah, M.A. CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. *Front. Cell Dev. Biol.* 2017, 5, 18. [CrossRef]

146. Vey, N.; Delaunay, J.; Martinelli, G.; Fiedler, W.; Raffoux, E.; Prebet, T.; Gomez-Roca, C.; Papayannis, C.; Kebenko, M.; Paschka, P.; et al. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. *Oncotarget* 2016, 7, 32532–32542. [CrossRef]

147. Macdonald, J.; Henri, J.; Roy, K.; Hays, E.; Bauer, M.; Veedu, R.N.; Shigdar, S. EpCAM immunotherapy versus specific targeted delivery of drugs. *Cancers* 2018, 10, 19. [CrossRef]

148. Ragnhammar, P.; Fagerberg, J.; Frödin, J.-E.; Hjelm, A.-L.; Lindemalm, C.; Magnusson, I.; Masucci, G.; Mellstedt, H. Effect of monoclonal antibody 17-1A and gm-CSF in patients with advanced colorectal carcinoma—long-lasting, complete remissions can be induced. *Int. J. Cancer* 1993, 53, 751–758. [CrossRef]

149. Riethmüller, G.; Schneider-Gädicke, E.; Schlimok, G.; Schmiegel, W.; Hö; Ragnhammar, P.; Fagerberg, J.; Frödin, J.-E.; Hjelm, A.-L.; Lindemalm, C.; Magnusson, I.; Masucci, G.; Mellstedt, H. Effect of monoclonal antibody 17-1A and gm-CSF in patients with advanced colorectal carcinoma—long-lasting, complete remissions can be induced. *Int. J. Cancer* 1993, 53, 751–758. [CrossRef]

150. Schmoll, H.-J.; Wittig, B.; Arnold, D.; Riera-Knorrenschild, J.; Nitsche, D.; Kroening, H.; Mayer, F.; Andel, J.; Ziebbermayr, R.; Scheithauer, W. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: A randomised, double-blind, placebo-controlled trial. *J. Cancer Res. Clin. Oncol.* 2014, 140, 1615–1624. [CrossRef]

151. Fields, A.L.; Keller, A.; Schwartzberg, L.; Bernard, S.; Kardinal, C.; Cohen, A.; Schulz, J.; Eisenberg, P.; Forster, J.; Wissel, P. Adjuvant therapy with the monoclonal antibody edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. *J. Clin. Oncol.* 2009, 27, 1941–1947. [CrossRef]

152. Münz, M.; Murr, A.; Kvesic, M.; Rau, D.; Mangold, S.; Pflanz, S.; Lumsden, J.; Volkland, J.; Fagerberg, J.; Riethmüller, G.; et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. *Cancer Cell Int.* 2010, 10, 44. [CrossRef]

153. Schmidt, M.; Scheulen, M.E.; Dittrich, C.; Obrist, P.; Marschner, N.; Dirix, L.; Schmidt, M.; Ruttinger, D.; Schuler, M.; Reinhardt, C.; et al. An open-label, randomized phase II study of adecatumab, a fully human anti-CD44 antibody, as monotherapy in patients with metastatic colorectal carcinoma. German Cancer Aid 17-A1 Study Group. *Lancet* 1994, 343, 1177–1183. [CrossRef]

154. Gao, A.-G.; Lindberg, F.P.; Finn, M.B.; Blystone, S.D.; Brown, E.J.; Frazier, W.A. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. *J. Biol. Chem.* 1996, 271, 21–24. [CrossRef]

155. Lindberg, F.P.; Bullard, D.C.; Caver, T.E.; Gresham, H.D.; Beaudet, A.L.; Brown, E.J. Decreased resistance to bacterial infection and granulocyte defects in IAP-Deficient mice. *Science* 1996, 274, 795–798. [CrossRef]

156. Miyashita, M.; Ohnishi, H.; Okazawa, H.; Tomonaga, H.; Hayashi, A.; Fujimoto, T.-T.; Furuya, N.; Matozaki, T. Promotion of neurite and filopodium formation by CD47: Roles of integrins, rac, and Cdc42. *Mol. Biol. Cell* 2004, 15, 3950–3963. [CrossRef]

157. Liu, Y.; Merlin, D.; Burst, S.L.; Pochet, M.; Madara, J.L.; Parkos, C.A. The role of CD47 in neutrophil transmigration: Increased rate of migration correlates with increased cell surface expression of cd47. *J. Boil. Chem.* 2001, 276, 40156–40166. [CrossRef]

158. Reinhold, M.I.; Lindberg, F.P.; Kersh, G.J.; Allen, P.M.; Brown, E.J. Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. *J. Exp. Med.* 1997, 185, 1–11. [CrossRef]
159. Jaiswal, S.; Jamieson, C.H.; Pang, W.W.; Park, C.Y.; Chao, M.P.; Majeti, R.; Traver, D.; Van Rooijen, N.; Weissman, I.L. CD47 is up-regulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. *Cell 2009*, *138*, 271–285. [CrossRef]

160. Kim, M.J.; Lee, J.-C.; Lee, J.-J.; Kim, S.; Lee, S.G.; Park, S.-W.; Sung, M.W.; Heo, D.S. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. *Tumor Biol.* *2008*, *29*, 28–34. [CrossRef]

161. Chao, M.P.; Alizadeh, A.A.; Tang, C.; Myklebust, J.H.; Varghese, B.; Gill, S.; Jan, M.; Cha, A.C.; Chan, C.K.; Tan, B.T.; et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. *Cell 2010*, *142*, 699–713. [CrossRef]

162. Chan, K.S.; Espinosa, I.; Chao, M.; Wong, D.; Ailles, L.; Diehn, M.; Gill, H.; Presti, J., Jr.; Chang, H.Y.; van de Rijn, M.; et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. *Proc. Natl. Acad. Sci. USA 2009*, *106*, 14016–14021. [CrossRef]

163. Manna, P.P.; Frazier, W.A. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. *Cancer Res.* *2004*, *64*, 1026–1036. [CrossRef]

164. Schulenburg, A.; Blatt, K.; Cerny-Reiterer, S.; Sadovnik, I.; Herrmann, H.; Marian, B.; Grunt, T.W.; Zielinski, C.C.; Valant, P. Cancer stem cells in basic science and in translational oncology: Can we translate into clinical application? *J. Hematol. Oncol.* *2015*, *8*, 16. [CrossRef]

165. Fan, G.; Wang, Z.; Hao, M.; Li, J. Bispecific antibodies and their applications. *J. Hematol. Oncol.* *2015*, *8*, 130. [CrossRef]

166. Fang, X.; Chen, C.; Xia, F.; Yu, Z.; Zhang, Y.; Zhang, F.; Gu, H.; Wan, J.; Zhang, X.; Weng, W.; et al. CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling. *J. Hematol. Oncol.* *2016*, *9*, 124. [CrossRef]

167. Zhao, H.; Wang, J.; Kong, X.; Li, E.; Liu, Y.; Du, X.; Kang, Z.; Tang, Y.; Kuang, Y.; Yang, Z.; et al. CD47 promotes tumor invasion and metastasis in non-small cell lung cancer. *Sci. Rep.* *2016*, *6*, 29719. [CrossRef]

168. Sikic, B.I.; Lakhani, N.; Patnaik, A.; Shah, S.A.; Chandana, S.R.; Rasco, D.; Colevas, A.D.; O’Rourke, T.; Narayanan, S.; Papadopoulos, K.; et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. *J. Clin. Oncol.* *2019*, *37*, 946–953. [CrossRef]

169. Liu, J.; Wang, L.; Zhao, F.; Tseng, S.; Narayanan, C.; Shura, L.; Willingham, S.; Howard, M.; Prohaska, S.; Volkmer, J.; et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. *PLoS ONE 2015*, *10*, e0137345. [CrossRef]

170. Liu, X.; Kwon, H.; Li, Z.; Fu, Y.-X. Is CD47 an innate immune checkpoint for tumor evasion? *J. Hematol. Oncol.* *2017*, *10*, 12. [CrossRef]

171. Advani, R.; Flinn, I.; Popplewell, L.; Forero, A.; Bartlett, N.L.; Ghosh, N.; Kline, J.; Roschewski, M.; LaCasce, A.; Collins, G.P.; et al. CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma. *New Engl. J. Med.* *2018*, *379*, 1711–1721. [CrossRef]

172. Huber, A.; Dammeyer, F.; Aerts, J.G.J.V.; Vroman, H. Current state of dendritic cell-based immunotherapy: Opportunities for in vitro antigen loading of different DC subsets? *Front. Immunol.* *2018*, *9*, 2804. [CrossRef]

173. Van Willigen, W.W.; Bloemendal, M.; Gerritsen, W.R.; Schreibelt, G.; De Vries, I.J.M.; Bol, K.F. Dendritic cell cancer therapy: Vaccinating the right patient at the right time. *Front. Immunol.* *2018*, *9*, 2265. [CrossRef]

174. Li, J.; Li, W.; Huang, K.; Zhang, Y.; Kupfer, G.; Zhao, Q. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: Lessons learned and strategies for moving forward. *J. Hematol. Oncol.* *2018*, *11*, 22. [CrossRef]

175. Lin, P.-C.; Hsieh, H.-Y.; Chu, P.-C.; Chen, C.S. Therapeutic opportunities of targeting histone deacetylase isoforms to eradicate cancer stem cells. *Int. J. Mol. Sci.* *2018*, *19*, 1939. [CrossRef]

176. Mele, L.; Paimo, P.; Papaccio, F.; Regad, T.; Boocock, D.; Stiuso, P.; Lombardi, A.; Liccardo, D.; Aquino, G.; Barbieri, A.; et al. A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. *Cell Death Dis.* *2018*, *9*, 572. [CrossRef]